The White House announced that pharmaceutical companies Abbvie and Genentech will officially join the TrumpRx program, expanding the range of discounted prescription drugs available to uninsured Americans or those without adequate insurance coverage. These two companies are the 10th and 11th to participate in the initiative, which aims to reduce drug costs for patients paying full list price.
Abbvie, which signed a discount agreement with the Trump administration in January, will offer Humira—a widely prescribed medication for rheumatoid arthritis, Crohn’s disease, and ulcerative colitis—at an 86% price reduction on the TrumpRx site. The Humira pen, which can cost over $6,900 for uninsured patients, will be available with a coupon lowering the price to around $950.
Genentech, which reached its agreement with the Trump administration in December, will provide Xofluza—a single-dose antiviral medication for treating and preventing the flu—through TrumpRx at approximately $50 per dose, down from the retail price of $168.
Another pharmaceutical firm, Amgen, plans to extend its participation by adding arthritis drug Enbrel and plaque psoriasis treatment Otezla to the TrumpRx platform. The program currently offers more than 61 discounted drugs, up from about 40 when it first launched in February 2026.
The discounted pricing on TrumpRx is primarily available for uninsured individuals or those whose insurance does not cover specific medications. People with insurance typically benefit from negotiated lower prices directly with their providers.
Why it matters
The TrumpRx initiative is part of the administration’s broader effort to reduce prescription drug costs in the United States by negotiating prices comparable to those in other countries. This includes “most-favored-nation” agreements that require pharmaceutical companies to sell medications to uninsured Americans at prices no higher than those in foreign markets.
Officials have also indicated ongoing work to integrate these discount deals into the “Great Healthcare Plan,” which would allow insured patients on government programs to use copays for TrumpRx drugs once Congress addresses the related legislation.
Read more Business stories on Goka World News.